Literature DB >> 25941590

Differential potency of regulatory T cell-mediated immunosuppression in kidney tumors compared to subcutaneous tumors.

Christel Devaud1, Jennifer A Westwood1, Michele Wl Teng2, Liza B John1, Carmen Sm Yong1, Connie Pm Duong1, Mark J Smyth3, Phillip K Darcy4, Michael H Kershaw4.   

Abstract

In many cancers, regulatory T cells (Treg) play a crucial role in suppressing the effector immune response thereby permitting tumor development. Indeed, in mouse models, their depletion can promote the regression of tumors of various origins, including renal cell carcinoma when located subcutaneous (SC). In the present study, we aimed to assess the importance of Treg immunosuppression in the physiologic context of metastatic renal carcinoma (Renca) disease. To that purpose we inoculated renal tumors orthotopically, intra-kidney (IK), in mice. Treg depletions were performed using anti-CD4 antibody in wild type mice or diphtheria toxin (DT) in Foxp3DTR transgenic mice. Our main observation was that Treg were not the key immunosuppressive component of the IK tumoral microenvironment, compared to the same tumors located SC. We demonstrated that the CD8+ effector immune response was still suppressed in IK tumors when compared to SC tumors, following Treg depletion. Furthermore, the level of program cell death protein (PD)-1 was increased on the surface of CD4+ T cells infiltrating IK tumors compared to SC tumors. Finally, the Treg-independent immunosuppression, occurring in IK tumors, was potent enough to inhibit regression of concomitant SC tumors, normally responsive to Treg depletion. Our findings provide further insight into the immunosuppressive nature of the immune response generated in the kidney microenvironment, suggesting that it can have additional mechanisms in addition to Treg. These observations might help to identify better targets from the kidney tumor microenvironment for future cancer therapies.

Entities:  

Keywords:  CD, cluster of differentiation; CTLA-4, cytotoxic T lymphocyte antigen 4; DEREG, Depletion of Regulatory T cells; DT, diphtheria toxin; DTR, diphtheria toxin receptor; FCS, fetal calf serum; FR, folate receptor; Foxp3, Forkhead box protein P3; IFN, interferon; IK, intra-kidney; IL, interleukin; IP, intra-peritoneal; IV, intravenously; M2, type-2 immunosuppressive macrophages; PBS, phosphate-buffered saline; PD-1, program cell death protein 1; PD-L1, PD ligand 1; Renca Ch+ L+, Renca Cherry Luciferase; SC, subcutaneous; T regulatory cells; TCR, T cell receptor; Th, T helper cells; Treg, regulatory T cells; depletion; immunosuppression; kidney tumors; mAb, monoclonal antibody; tumor microenvironment

Year:  2014        PMID: 25941590      PMCID: PMC4368122          DOI: 10.4161/21624011.2014.963395

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  35 in total

Review 1.  Immunosuppressive networks in the tumour environment and their therapeutic relevance.

Authors:  Weiping Zou
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

Review 2.  Natural innate and adaptive immunity to cancer.

Authors:  Matthew D Vesely; Michael H Kershaw; Robert D Schreiber; Mark J Smyth
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

3.  Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice.

Authors:  Jeong M Kim; Jeffrey P Rasmussen; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2006-11-30       Impact factor: 25.606

Review 4.  Regulatory T cells in tumor immunity.

Authors:  Hiroyoshi Nishikawa; Shimon Sakaguchi
Journal:  Int J Cancer       Date:  2010-08-15       Impact factor: 7.396

Review 5.  The PD-1 pathway in tolerance and autoimmunity.

Authors:  Loise M Francisco; Peter T Sage; Arlene H Sharpe
Journal:  Immunol Rev       Date:  2010-07       Impact factor: 12.988

6.  Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy.

Authors:  Christel Devaud; Jennifer A Westwood; Liza B John; Jacqueline K Flynn; Sophie Paquet-Fifield; Connie P M Duong; Carmen S M Yong; Hollie J Pegram; Steven A Stacker; Marc G Achen; Trina J Stewart; Linda A Snyder; Michele W L Teng; Mark J Smyth; Phillip K Darcy; Michael H Kershaw
Journal:  Mol Ther       Date:  2013-09-19       Impact factor: 11.454

7.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

Review 8.  Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy.

Authors:  Mario P Colombo; Silvia Piconese
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

9.  Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease.

Authors:  Katharina Lahl; Christoph Loddenkemper; Cathy Drouin; Jennifer Freyer; Jon Arnason; Gérard Eberl; Alf Hamann; Hermann Wagner; Jochen Huehn; Tim Sparwasser
Journal:  J Exp Med       Date:  2007-01-02       Impact factor: 14.307

10.  Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors.

Authors:  Ping Yu; Youjin Lee; Wenhua Liu; Thomas Krausz; Anita Chong; Hans Schreiber; Yang-Xin Fu
Journal:  J Exp Med       Date:  2005-03-07       Impact factor: 14.307

View more
  6 in total

1.  A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies.

Authors:  Katherine A Murphy; Britnie R James; Andrew Wilber; Thomas S Griffith
Journal:  J Vis Exp       Date:  2017-04-12       Impact factor: 1.355

2.  Functional role of regulatory T cells in B cell lymphoma and related mechanisms.

Authors:  Wei Wu; Jun Wan; Ruixiang Xia; Zhenqi Huang; Jing Ni; Mingzhen Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

Review 3.  PD-1/PD-L1 blockade in renal cell cancer.

Authors:  Kathryn E Beckermann; Douglas B Johnson; Jeffrey A Sosman
Journal:  Expert Rev Clin Immunol       Date:  2016-07-28       Impact factor: 4.473

4.  Valproic Acid-Like Compounds Enhance and Prolong the Radiotherapy Effect on Breast Cancer by Activating and Maintaining Anti-Tumor Immune Function.

Authors:  Zuchao Cai; David Lim; Guochao Liu; Chen Chen; Liya Jin; Wenhua Duan; Chenxia Ding; Qingjie Sun; Junxuan Peng; Chao Dong; Fengmei Zhang; Zhihui Feng
Journal:  Front Immunol       Date:  2021-05-12       Impact factor: 7.561

5.  Protean role of epigenetic mechanisms and their impact in regulating the Tregs in TME.

Authors:  A S Smiline Girija
Journal:  Cancer Gene Ther       Date:  2021-07-28       Impact factor: 5.854

Review 6.  Immuno-Oncology: Emerging Targets and Combination Therapies.

Authors:  Henry T Marshall; Mustafa B A Djamgoz
Journal:  Front Oncol       Date:  2018-08-23       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.